OKYO

OKYO Pharma
OKYO

$1.04

2.36%

Market Cap: $35M

About: OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Employees: 3

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

17% more funds holding

Funds holding: 6 [Q1] → 7 (+1) [Q2]

0.29% more ownership

Funds ownership: 2.75% [Q1] → 3.04% (+0.29%) [Q2]

11% less capital invested

Capital invested by funds: $1.36M [Q1] → $1.21M (-$154K) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

576%

upside

Avg. target

$7

576%

upside

High target

$7

576%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen 43% 1-year accuracy 58 / 136 met price target	576%upside $7	Buy Reiterated	27 Aug 2024
HC Wainwright & Co. Yi Chen 43% 1-year accuracy 58 / 136 met price target	576%upside $7	Buy Reiterated	12 Jul 2024
HC Wainwright & Co. Yi Chen 43% 1-year accuracy 58 / 136 met price target	576%upside $7	Buy Reiterated	11 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about OKYO published over the past 30 days

Proactive Investors

OKYO Pharma secures key US patent for dry eye disease therapy

OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients with dry eye disease (DED) The patent, issued on August 6, is US patent no. 12,053,503 titled “Methods for Treating Symptoms of Dry Eye Disease.

OKYO Pharma secures key US patent for dry eye disease therapy

OKYO Pharma CEO Interview to Air on Bloomberg TV

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today an interview with its CEO, Dr. Gary S. Jacob will air on The RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 24, at 7 p.m.

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company's ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.

OKYO Pharma Announces Chairman Acquires Shares

Proactive Investors

OKYO Pharma chairman acquires more shares in the company

OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares of the company at $1 each. The company said the purchase brings Cerrone's total shareholding to 9,671,570 shares, or 28.58% of issued share capital.

OKYO Pharma chairman acquires more shares in the company

OKYO Pharma Announces Chairman Acquires Shares

LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 35,000 of the Company's ordinary shares on NASDAQ at a price of US$1.00 per share. This brings the total shareholding of Mr Cerrone to 9,671,570 shares which is 28.58% of issued share capital.

OKYO Pharma Announces Chairman Acquires Shares

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the company will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, which is being held on Thursday, August 15th.

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Proactive Investors

OKYO Pharma lands European patent protection for lead asset

OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, strengthening the drug developer's intellectual property in ocular inflammatory and pain conditions.

OKYO Pharma lands European patent protection for lead asset

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key European Patent entitled: “Compositions Comprising Chemerin Analogs and Methods of Use”. The present disclosure that lists Raj Patil, Chief Scientific Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101 chemerin analogs for use in treating various diseases and conditions including but not limited to, ocular inflammatory and pain conditions, strengthening the Company's intellectual property position in this field.

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Proactive Investors

OKYO Pharma dry eye disease trial to get underway in the third quarter

OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain relief for dry eye disease patients and reduced NCP in animal models.

OKYO Pharma dry eye disease trial to get underway in the third quarter

See News Rankings